The FDA approved Novocure’s Optune Pax, a wearable tumor-treating fields device, for pancreatic cancer in combination with chemotherapy. Phase III PANOVA-3 data showed delayed pain progression and improved one-year overall survival in inoperable locally advanced disease.
The FDA cleared neuromodulation devices from Epineuron, Aneuvo and Encora Therapeutics. The products address peripheral nerve surgery, spinal cord injury neurorehabilitation and essential tremor.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07707986 |
Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use |
NOT_YET_RECRUITING | PHASE1 |
| NCT07703969 |
Safety of Topical Exosome-Containing Liquid in Healthy Volunteers |
NOT_YET_RECRUITING | PHASE1 |
